Ex-Ante-Transparenzbekanntmachung § 130a Abs. 8 SGB V Lytenava(R) Wirkstoff: Bevacizumab gamma ATC-Code: S01LA08
Tender information
DE_BKMSMünchen, Germany
- Type
- goods
- Procedure
- Negotiated without prior call for competition
- Ref. number
- af6bcd3a-e332-4061-a1df-b70e3ac69f2d
- CPV
- 33600000
Arzneimittelrabattvertrag § 130a Abs. 8 SGB V Arzneimittelbezeichnung: Lytenava(R) Wirkstoff: Bevacizumab gamma ATC-Code: S01LA08